CeriBell’s Lock-Up Period Will Expire Tomorrow (NASDAQ:CBLL)

CeriBell’s (NASDAQ:CBLL) lock-up period is set to end on Wednesday, April 9th. CeriBell had issued 10,606,060 shares in its initial public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on CBLL shares. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday. They issued a “buy” rating and a $32.00 price objective for the company. Canaccord Genuity Group restated a “buy” rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Finally, TD Cowen boosted their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.50.

CeriBell Trading Down 1.4 %

NASDAQ:CBLL opened at $18.19 on Tuesday. The firm has a 50-day moving average price of $21.86. CeriBell has a fifty-two week low of $17.24 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. As a group, equities research analysts forecast that CeriBell will post -2.46 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CBLL. FMR LLC purchased a new stake in shares of CeriBell during the fourth quarter worth about $128,120,000. TPG GP A LLC acquired a new stake in CeriBell in the 4th quarter worth approximately $102,677,000. Red Tree Management LLC purchased a new stake in CeriBell during the 4th quarter worth approximately $57,083,000. Yu Fan acquired a new position in CeriBell during the 4th quarter valued at approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in shares of CeriBell in the fourth quarter worth $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.